Holen Sie sich die Stockscreener-App
93.00
16.13%
12.92
Schlusskurs vom Vortag:
$80.08
Offen:
$81.5
24-Stunden-Volumen:
14.01M
Relative Volume:
9.13
Marktkapitalisierung:
$7.10B
Einnahmen:
$8.10B
Nettoeinkommen (Verlust:
$599.48M
KGV:
12.57
EPS:
7.3969
Netto-Cashflow:
$971.50M
1W Leistung:
-38.24%
1M Leistung:
-49.26%
6M Leistung:
-47.25%
1J Leistung:
-49.08%
1-Tages-Spanne:
$81.31
$96.55
1-Wochen-Bereich:
$66.57
$155.00
52-Wochen-Spanne:
$66.57
$211.00
Icon Plc Stock (ICLR) Company Profile
Firmenname
Icon Plc
Sektor
Branche
Telefon
-
Adresse
-
Compare ICLR vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
93.00 | 6.11B | 8.10B | 599.48M | 971.50M | 7.3969 |
|
TMO
Thermo Fisher Scientific Inc
|
504.82 | 191.54B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
212.58 | 151.94B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
629.35 | 49.28B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
125.81 | 35.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
323.37 | 31.37B | 3.17B | 642.63M | 539.81M | 10.77 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2026-02-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-01-08 | Herabstufung | Truist | Buy → Hold |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2025-09-09 | Herabstufung | Jefferies | Buy → Hold |
| 2025-09-03 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2025-08-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-07-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-04-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-04-14 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-04-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-09-18 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2023-12-15 | Eingeleitet | Truist | Buy |
| 2023-09-13 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-17 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-01-13 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-11-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-09-07 | Eingeleitet | UBS | Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-05-24 | Eingeleitet | Guggenheim | Buy |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2021-09-27 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-14 | Eingeleitet | Citigroup | Neutral |
| 2021-04-13 | Fortgesetzt | BofA Securities | Neutral |
| 2021-04-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | Eingeleitet | Barclays | Equal Weight |
| 2021-03-01 | Hochstufung | UBS | Neutral → Buy |
| 2021-02-26 | Hochstufung | Truist | Hold → Buy |
| 2020-07-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-04-20 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Hold |
| 2020-01-27 | Herabstufung | SunTrust | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-09-23 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | Hochstufung | UBS | Sell → Neutral |
| 2019-01-25 | Hochstufung | Mizuho | Neutral → Buy |
| 2018-10-26 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-10-09 | Eingeleitet | UBS | Sell |
| 2018-04-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-15 | Bestätigt | Mizuho | Neutral |
| 2018-01-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-10-27 | Bestätigt | Barclays | Equal Weight |
| 2017-09-11 | Eingeleitet | BofA/Merrill | Buy |
| 2017-07-31 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-27 | Bestätigt | Mizuho | Neutral |
| 2017-06-29 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Icon Plc Aktie (ICLR) Neueste Nachrichten
ICON Public Limited Company (ICLR) Delays Earnings Amid Internal Investigation - Finviz
US law firms circle Icon PLC after revelations of accounting probe send shares plunging - The Irish Independent
ICON PLC (ICON) Soars 16% as Analyst Issues 'Hold', $93 PT Despite Accounting Concerns - Finviz
ICON PLC (ICON) Soars 16% as Analyst Issues ‘Hold’, $93 PT Despite Accounting Concerns - Insider Monkey
ICON (ICLR) stock rebounds after accounting probe shock — what investors watch next - Bez Kabli
ICON plc Expands Oncology Research, Sets New Price Target - StocksToTrade
Icon Strategy Expands with New Partnership to Bolster Oncology Research - timothysykes.com
ICON Expands Oncology Research Capabilities Amidst Positive Stock Reevaluation - StocksToTrade
ICON plc Expands Clinical Trial Capabilities through Strategic Partnership - timothysykes.com
Icon Partners with Brian Moran for Key Oncology Expansion - StocksToTrade
ICON plc Expands Oncology Network, Stock Assessment and Market Analysis - timothysykes.com
ICON plc Expands Oncology Research, Price Target Upgraded - StocksToTrade
ICON plc (ICLR) Shares Crater Amid Delayed Financial Report, Investigation Into Revenue Recognition IssuesHagens Berman - The Malaysian Reserve
ICON (ICLR) Is Down 44.9% After Probing Revenue Recognition And Control WeaknessesWhat's Changed - Yahoo Finance
ICON plc (ICLR) Shares Crater Amid Delayed Financial Report, Inv - GuruFocus
ICON (ICLR) stock steadies premarket after 40% crash on accounting probe — what’s next - Bez Kabli
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ICON plc (ICLR) And Encourages Investors to Reach Out - ACCESS Newswire
ICON stock plummets after accounting investigation delays earnings By Investing.com - Investing.com
ICON stock rating suspended by Evercore amid accounting investigation By Investing.com - Investing.com Canada
Icon PLC stock hits 52-week low at $79.49 By Investing.com - Investing.com Canada
ICON stock rating downgraded by BofA Securities amid accounting concerns - Investing.com UK
Ademi LLP Investigates Claims of Securities Fraud against ICON plc - The Malaysian Reserve
ICON Public Limited Company Under Investigation for Securities Law Violations - Intellectia AI
ICON plc Shares Plunge 49% Amid Revenue Recognition Investigation - Intellectia AI
ICON plc (ICLR) Shares Crater Amid Delayed Financial - GlobeNewswire
Medtech Plummets 40% On Profit-Threatening Investigation - Investor's Business Daily
U.S. Indexes Decreased Thursday; Icon PLC Posted Biggest Loss - Barron's
ICON Shares Plunge 50% After Revenue Overstatement Disclosure - GuruFocus
Icon PLC to delay results, says revenue may have been overstated in 2023 and 2024 - MSN
ICON (ICLR) Shares Plummet Amid Accounting Probe - GuruFocus
Ademi LLP Investigates Claims of Securities Fraud against ICON p - GuruFocus
ICON stock rating reiterated at Hold by TD Cowen amid accounting probe By Investing.com - Investing.com Nigeria
ICON stock rating reiterated at Hold by TD Cowen amid accounting probe - Investing.com UK
Shares in Icon Plc plunge 40% amid internal accounting investigation - Business Post
ICON stock sinks nearly 40% after accounting probe pulls guidance; what investors watch next - Bez Kabli
INVESTOR ALERT: Investigation of ICON plc (ICLR) by Holzer & Holzer, LLC - GlobeNewswire
Jefferies maintains Hold rating on ICON stock at $175 price target By Investing.com - Investing.com Nigeria
Truist Securities reiterates Hold rating on ICON stock amid accounting probe By Investing.com - Investing.com Nigeria
Truist Securities reiterates Hold rating on ICON stock amid accounting probe - Investing.com UK
Rosen Law Firm Encourages ICON plc Investors to Inquire About Securities Class Action Investigation – ICLR - The AI Journal
ICON stock price target lowered to $100 by BMO Capital on accounting probe By Investing.com - Investing.com Canada
Why this drug-research company’s stock had its worst day since 1999 - MarketWatch
ICON (ICLR) stock price tumbles 40% after accounting probe delays 2025 results - Bez Kabli
Icon (ICLR) Shares Plummet by 40% Amid Market Volatility - GuruFocus
Icon (ICLR) Faces Rating Suspension Amidst Accounting Investigat - GuruFocus
Icon (ICLR) Faces Downgrade Amid Ongoing Accounting Investigatio - GuruFocus
Leerink Partners downgrades ICON stock rating to Market Perform on accounting concerns - Investing.com UK
Leerink Partners downgrades ICON stock rating to Market Perform on accounting concerns By Investing.com - Investing.com Nigeria
ICON stock rating downgraded by BofA Securities amid accounting concerns By Investing.com - Investing.com South Africa
ICON Shares Slump Amid Internal Investigation - 富途牛牛
ICON PLC (ICLR) Shareholders Are Encouraged to Reach Out to - GlobeNewswire
Finanzdaten der Icon Plc-Aktie (ICLR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):